TY - JOUR

T1 - Serum Bactericidal Activity of Piperacillin/Tazobactam against Staphylococcus Aureus, Piperacillin-Susceptible and Piperacillin-Resistant Escherichia Coli and Pseudomonas Aeruginosa

AU - Lemmen, Sebastian W.

AU - Zolldann, Dirk

AU - Klik, S.

AU - Lutticken, Rudolf

AU - Kümmerer, Klaus

AU - Hafner, Helga

PY - 2004/1/1

Y1 - 2004/1/1

N2 - Background: The serum bactericidal test measures the highest level of an antibiotic-containing serum dilution at which 99.9% of bacteria are killed. In this study the serum bactericidal activity of piperacillin/tazobactam was determined for bacteria often involved in severe infections. In earlier studies titres ≥1:8 in the serum bactericidal tests correlated well with clinical success in the treatment of endocarditis and osteomyelitis as well as bacterial eradication. Methods: Blood samples of 6 healthy volunteers were taken before and 1 and 4 h after piperacillin/tazobactam (4.5 g) administration. Serum concentrations and serum bactericidal activity were determined for 10 strains each of Staphylococcus aureus, Pseudomonas aeruginosa and Escherichia coli, both piperacillin-resistant and piperacillin-susceptible according to NCCLS guidelines. Results: 100% of S. aureus and piperacillin-susceptible E. coli, 90% of piperacillin-resistant E. coli and 80% of P. aeruginosa were killed 1 h after drug administration. 4 h after drug administration serum bactericidal activity decreased to 60% for S. aureus, 90% for piperacillin-susceptible E. coli, 80% for piperacillin-resistant E. coli and 30% for P. aeruginosa. Conclusions: Excellent serum bactericidal activity of piperacillin/tazobactam was recorded 1 h after drug administration for S. aureus, E. coli and P. aeruginosa. After 4 h limited killing rates for P. aeruginosa could be detected, which supports the idea of a combination therapy. Copyright © 2004 S. Karger AG, Basel.

AB - Background: The serum bactericidal test measures the highest level of an antibiotic-containing serum dilution at which 99.9% of bacteria are killed. In this study the serum bactericidal activity of piperacillin/tazobactam was determined for bacteria often involved in severe infections. In earlier studies titres ≥1:8 in the serum bactericidal tests correlated well with clinical success in the treatment of endocarditis and osteomyelitis as well as bacterial eradication. Methods: Blood samples of 6 healthy volunteers were taken before and 1 and 4 h after piperacillin/tazobactam (4.5 g) administration. Serum concentrations and serum bactericidal activity were determined for 10 strains each of Staphylococcus aureus, Pseudomonas aeruginosa and Escherichia coli, both piperacillin-resistant and piperacillin-susceptible according to NCCLS guidelines. Results: 100% of S. aureus and piperacillin-susceptible E. coli, 90% of piperacillin-resistant E. coli and 80% of P. aeruginosa were killed 1 h after drug administration. 4 h after drug administration serum bactericidal activity decreased to 60% for S. aureus, 90% for piperacillin-susceptible E. coli, 80% for piperacillin-resistant E. coli and 30% for P. aeruginosa. Conclusions: Excellent serum bactericidal activity of piperacillin/tazobactam was recorded 1 h after drug administration for S. aureus, E. coli and P. aeruginosa. After 4 h limited killing rates for P. aeruginosa could be detected, which supports the idea of a combination therapy. Copyright © 2004 S. Karger AG, Basel.

KW - Pharmacodynamic

KW - Pharmacokinetic

KW - Piperacillin/tazobactam

KW - Serum bactericidal activity

KW - β-lactamase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=1842830030&partnerID=8YFLogxK

UR - https://www.mendeley.com/catalogue/74ebff6e-46af-358f-b59a-53a772613099/

U2 - 10.1159/000077281

DO - 10.1159/000077281

M3 - Journal articles

VL - 50

SP - 27

EP - 30

JO - Chemotherapy - International Journal of Experimental and Clinical Chemotherapy

JF - Chemotherapy - International Journal of Experimental and Clinical Chemotherapy

SN - 0009-3157

IS - 1

ER -